Skip to main content

Table 2 Baseline characteristics of participants by treatment groups

From: A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease

 

Roxithromycin/Doxycycline

Roxithromycin alone

Placebo

Number of patients

101

97

94

  Age (year), mean (SD)

65.8 (7.9)

67.6 (7.85)

66.7 (8.7)

  Male, n (%)

64 (63.37 %)

83 (85.57 %)

67 (71.28 %)

Race, n (%)

   

  New Zealand European

99 (98.02 %)

96 (98.97 %)

92 (97.87 %)

  Maori/Pacific Islander

1 (0.99 %)

1 (1.03 %)

1 (1.06 %)

  Other

1 (0.99 %)

0

1 (1.06 %)

  Height (cm), mean (SD)

168.6 (9.3)

171.4 (7.95)

169.5 (8.2)

  Weight (kg), mean (SD)

70.85 (14.6)

72.8 (14.8)

74.5 (19.7)

Smoking history, n (%)

   

  Current smoker

36 (35.64 %)

17 (17.53 %)

18 (19.15 %)

  Ex-smoker

65 (64.36 %)

80 (82.47 %)

76 (80.85 %)

  Average tobacco consumption (pack year), mean (SD)

57.96 (30.8)

54.36 (39)

57.38 (29.5)

  Number of previous exacerbations within 2 years, mean (SD)

5.01 (2.34)

5.39 (2.56)

4.93 (2.29)

Spirometry

   

  FEV1 (l), mean (SD)

0.85 (0.325)

0.965 (0.455)

0.99 (0.49)

  FEV1 (% predicted), mean (SD)

32.53 (13.55)

33.93 (15.3)

35.8 (15.2)

  FVC (l), mean (SD)

2.11 (0.78)

2.33 (0.82)

2.25 (0.9)

  FEV1/FVC mean (SD)

41.54 (10)

41.5 (10.8)

43.7 (9.9)

CRQ

   

  Dyspnoea, median (Min-Max)

15 (5 – 28)

15 (7 – 24)

16 (6 – 31)

  Fatigue, median (Min-Max)

15 (5 – 25)

16 (5 – 26)

15 (5 – 26)

  Emotional function, median (Min-Max)

33 (13 – 47)

33 (15 – 48)

32 (12 – 49)

  Mastery, median (Min-Max)

21 (5 – 28)

21 (7 – 28)

19 (7 – 28)

Co-morbidity (n, %)

   

  Ischaemic heart disease

6 (5.94 %)

11 (11.34 %)

13 (13.83 %)

  Hypertension

36 (35.64 %)

39 (40.21 %)

33 (35.11 %)

  Abnormal liver function

1 (0.99 %)

1 (1.03 %)

1 (1.06 %)

  Gastroesophageal reflux disease

17 (16.83 %)

15 (15.46 %)

18 (19.15 %)